Newsroom
Inflammatix in the news
Inflammatix collects $57M as it awaits FDA review of infectious disease test
September 12, 2024
Targeting FDA OK for its test against deadly sepsis, South Bay company raises $57 million
September 12, 2024
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up
January 2, 2024
Inflammatix sepsis test scores FDA breakthrough device designation
November 28, 2023
Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test
November 28, 2023
Your medical devices are getting smarter. Can the FDA keep them safe?
October 9, 2023
Point-of-care testing for infectious diseases in emergency settings
January 18, 2023
Do Your Genes Know What’s Making You Sick?
January 6, 2022
Press releases
November 15, 2023
Inflammatix Completes Technical Development for TriVerity™ Acute Infection and Sepsis Test System
September 13, 2023
UMCG and Inflammatix Collaborate to Improve Early Recognition and Clinical Decision Support for Sepsis Care
July 10, 2023
Inflammatix Appoints Heiner Dreismann as New Board Member
June 15, 2022
Inflammatix Appoints Dr. Purvesh Khatri as Chief Scientific Officer
November 30, 2021
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
November 18, 2021
Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test
November 11, 2021
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
March 16, 2021
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Machine learning blogs
Podcasts
Diagnosing Infection with Ljubomir Buturovic from Inflammatix
December 2023
Advances in Sepsis Diagnostics: the HostDx Sepsis Platform
May 2018